TARS

SEC source: 0001827672-23-000022 · wf-form4_167961543559554.xml · nonDerivative · entry 2

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,334

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001839516-23-000004 · wf-form4_167961530701522.xml · nonDerivative · entry 2

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,564

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the previously reported vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001788542-23-000004 · wf-form4_167961515955541.xml · nonDerivative · entry 2

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,201

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001519692-23-000010 · wf-form4_167961628683110.xml · nonDerivative · entry 1

Greenstein Leonard M. · CIK 0001519692 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,463

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001661539-23-000004 · wf-form4_167961616570410.xml · nonDerivative · entry 1

Trevejo Jose M. · CIK 0001661539 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,101

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001827584-23-000004 · wf-form4_167961578319952.xml · nonDerivative · entry 1

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,465

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001841401-23-000004 · wf-form4_167961555155059.xml · nonDerivative · entry 1

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,130

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001827672-23-000022 · wf-form4_167961543559554.xml · nonDerivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,043

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001839516-23-000004 · wf-form4_167961530701522.xml · nonDerivative · entry 1

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,897

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the previously reported vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001788542-23-000004 · wf-form4_167961515955541.xml · nonDerivative · entry 1

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,558

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001839516-23-000002 · wf-form4_167944061665243.xml · nonDerivative · entry 2

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,223

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the previously reported vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001841401-23-000002 · wf-form4_167944048401877.xml · nonDerivative · entry 2

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,480

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001827584-23-000002 · wf-form4_167944035754056.xml · nonDerivative · entry 2

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,837

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001661539-23-000002 · wf-form4_167944023837852.xml · nonDerivative · entry 2

Trevejo Jose M. · CIK 0001661539 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,620

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001788542-23-000002 · wf-form4_167944011481271.xml · nonDerivative · entry 2

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,907

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001827564-23-000002 · wf-form4_167943994647637.xml · nonDerivative · entry 2

Holdbrook Mark J. · CIK 0001827564 · V.P., Clinical Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,191

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001519692-23-000008 · wf-form4_167943982457262.xml · nonDerivative · entry 2

Greenstein Leonard M. · CIK 0001519692 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,789

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001827672-23-000020 · wf-form4_167943965959717.xml · nonDerivative · entry 2

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,722

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001839516-23-000002 · wf-form4_167944061665243.xml · nonDerivative · entry 1

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,556

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the previously reported vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001841401-23-000002 · wf-form4_167944048401877.xml · nonDerivative · entry 1

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,837

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001827584-23-000002 · wf-form4_167944035754056.xml · nonDerivative · entry 1

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,217

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001661539-23-000002 · wf-form4_167944023837852.xml · nonDerivative · entry 1

Trevejo Jose M. · CIK 0001661539 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,150

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001788542-23-000002 · wf-form4_167944011481271.xml · nonDerivative · entry 1

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,265

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001827564-23-000002 · wf-form4_167943994647637.xml · nonDerivative · entry 1

Holdbrook Mark J. · CIK 0001827564 · V.P., Clinical Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,389

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001519692-23-000008 · wf-form4_167943982457262.xml · nonDerivative · entry 1

Greenstein Leonard M. · CIK 0001519692 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,122

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001827672-23-000020 · wf-form4_167943965959717.xml · nonDerivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,463

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001209191-23-019885 · doc4.xml · nonDerivative · entry 2

Holdbrook Mark J. · CIK 0001827564 · V.P., Clinical Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,577

F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001209191-23-019884 · doc4.xml · nonDerivative · entry 2

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,176

F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001209191-23-019883 · doc4.xml · nonDerivative · entry 2

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,872

F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001209191-23-019880 · doc4.xml · nonDerivative · entry 2

Trevejo Jose M. · CIK 0001661539 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,654

F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001209191-23-019879 · doc4.xml · nonDerivative · entry 2

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,604

F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001209191-23-019876 · doc4.xml · nonDerivative · entry 2

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,577

F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001519692-23-000006 · wf-form4_167909066577368.xml · nonDerivative · entry 3

Greenstein Leonard M. · CIK 0001519692 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,438

F3 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022.

F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $13.28 to $13.65. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001519692-23-000006 · wf-form4_167909066577368.xml · nonDerivative · entry 2

Greenstein Leonard M. · CIK 0001519692 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,438

F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001827672-23-000018 · wf-form4_167909053944482.xml · nonDerivative · entry 3

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,258

F5 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholdingobligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001209191-23-019891 · doc4.xml · nonDerivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Flying L Partners XI, LLC

Disclosed balance after: 68,673

F3 · kind: Represents the receipt of shares from a pro-rata in-kind distribution, and not a purchase or sale, without additional consideration by Flying L Investments XI, LLC to its partners.

F4 · ownership.nature: The shares are held directly held by Flying L Partners XI, LLC. The Reporting Person is the manager of Flying L Partners XI, LLC and may be deemed to have sole voting and investment power over the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.

SEC source: 0001209191-23-019891 · doc4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Flying L Investments XI, LLC

Disclosed balance after: 215,576

F1 · kind: Represents an in-kind pro-rata distribution, and not a purchase or sale, without additional consideration by Flying L Investments XI, LLC to its partners pursuant to a 10b5-1 plan entered into by Flying L Investments XI, LLC.

F2 · ownership.nature: The shares are held directly held by Flying L Investments XI, LLC. The Reporting Person is the manager of Flying L Investments XI, LLC and may be deemed to have sole voting and investment power over the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.

SEC source: 0001209191-23-019885 · doc4.xml · derivative · entry 3

Holdbrook Mark J. · CIK 0001827564 · V.P., Clinical Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,959

Underlying: Common Stock · 2,653 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock.

F5 · derivative.exercise_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

F5 · derivative.expiration_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

SEC source: 0001209191-23-019885 · doc4.xml · nonDerivative · entry 1

Holdbrook Mark J. · CIK 0001827564 · V.P., Clinical Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,764

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

F2 · balance_after: Includes 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022.

SEC source: 0001209191-23-019884 · doc4.xml · derivative · entry 3

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,370

Underlying: Common Stock · 4,790 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock.

F4 · derivative.exercise_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

F4 · derivative.expiration_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

SEC source: 0001209191-23-019884 · doc4.xml · nonDerivative · entry 1

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,513

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

SEC source: 0001209191-23-019883 · doc4.xml · derivative · entry 3

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,388

Underlying: Common Stock · 4,462 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock.

F4 · derivative.exercise_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

F4 · derivative.expiration_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

SEC source: 0001209191-23-019883 · doc4.xml · nonDerivative · entry 1

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,185

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

SEC source: 0001209191-23-019880 · doc4.xml · derivative · entry 3

Trevejo Jose M. · CIK 0001661539 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,648

Underlying: Common Stock · 7,549 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock.

F5 · derivative.exercise_date: RSU granted on February 1, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

F5 · derivative.expiration_date: RSU granted on February 1, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

SEC source: 0001209191-23-019880 · doc4.xml · nonDerivative · entry 1

Trevejo Jose M. · CIK 0001661539 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,153

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

F2 · balance_after: includes 1,604 shares acquired under the Issuer's employee stock purchase plan on December 31, 2022.

SEC source: 0001209191-23-019879 · doc4.xml · derivative · entry 3

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,370

Underlying: Common Stock · 4,790 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock.

F5 · derivative.exercise_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

F5 · derivative.expiration_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

SEC source: 0001209191-23-019879 · doc4.xml · nonDerivative · entry 1

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,940

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

F2 · balance_after: Includes 421 shares acquired under the Issuer's employee stock purchase plan on December 31, 2022.

SEC source: 0001209191-23-019876 · doc4.xml · derivative · entry 3

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,291

Underlying: Common Stock · 5,097 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock.

F5 · derivative.exercise_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

F5 · derivative.expiration_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

SEC source: 0001209191-23-019876 · doc4.xml · nonDerivative · entry 1

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,934

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

F2 · balance_after: Includes 862 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and includes 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022.

SEC source: 0001519692-23-000006 · wf-form4_167909066577368.xml · derivative · entry 4

Greenstein Leonard M. · CIK 0001519692 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,388

Underlying: Common Stock · 4,462 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock.

F6 · derivative.exercise_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2023, March 15, 2024, March 15, 2025 and March 15, 2026, subject to the Reporting Person's continuous service.

F6 · derivative.expiration_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2023, March 15, 2024, March 15, 2025 and March 15, 2026, subject to the Reporting Person's continuous service.